rs770485731
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000153.4(GALC):c.1186C>T(p.Arg396Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000144 in 1,599,058 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R396L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000153.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GALC | NM_000153.4 | c.1186C>T | p.Arg396Trp | missense_variant | 11/17 | ENST00000261304.7 | NP_000144.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000276 AC: 4AN: 145134Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000161 AC: 4AN: 248096Hom.: 0 AF XY: 0.00000743 AC XY: 1AN XY: 134674
GnomAD4 exome AF: 0.0000131 AC: 19AN: 1453924Hom.: 0 Cov.: 28 AF XY: 0.0000166 AC XY: 12AN XY: 723630
GnomAD4 genome AF: 0.0000276 AC: 4AN: 145134Hom.: 0 Cov.: 32 AF XY: 0.0000285 AC XY: 2AN XY: 70236
ClinVar
Submissions by phenotype
Galactosylceramide beta-galactosidase deficiency Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant c.1186C>T (p.Arg396Trp) in GALC gene has been reported in compound heterozygous state in individuals affected with Krabbe disease (Tappino B. et al., 2010). Experimental studies have shown that this missense demonstrated less compactness and reduced number of intramolecular hydrogen bonds indicating loss of protein stability (D TK. et al., 2021). This variant is reported with the allele frequency (0.001%) in the gnomAD and novel in 1000 genome database. It has been submitted to ClinVar as a Pathogenic variant. The amino acid Arginine at position 396 is changed to a Tryptophan changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. For these reasons, this variant has been classified as Pathogenic. No significant reportable GALC variant was detected in the spouse. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 12, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 396 of the GALC protein (p.Arg396Trp). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with Krabbe Disease (PMID: 3362311, 9338580, 26795590, 27638592; Invitae). This variant is also known as R380W. ClinVar contains an entry for this variant (Variation ID: 456712). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALC protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GALC function (PMID: 21876145, 24297913, 27638593). For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, no assertion criteria provided | clinical testing | Counsyl | May 09, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 13, 2022 | Variant summary: GALC c.1186C>T (p.Arg396Trp) results in a non-conservative amino acid change located in the Glycosyl hydrolase family 59, central domain (IPR035394) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 248096 control chromosomes (gnomAD). c.1186C>T has been reported in the literature in multiple individuals affected with Krabbe Disease (e.g. Wenger_1997, Tappino_2010, Orsini_2016, Krieg_2020, Bascou_2020). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function and showed that this variant causes significant decrease of GALC activity (Saavedra-Martiz_2016). Seven ClinVar submitters have assessed the variant since 2014: 1 classified the variant as likely pathogenic and six pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 07, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000456712, PMID:9338580, PS1_S). Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product (PMID: 21876145, 24297913, 27638593, PS3_M). A different missense change at the same codon has been reported to be associated with GALC related disorder (PMID:27779215,11151421, PM5_P). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.914, 3CNET: 0.917, PP3_P). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000016, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 20, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 23, 2023 | Published functional studies demonstrate a damaging effect with reduced GALC activity (Saaverda-Matiz et al., 2016); Not observed at a significant frequency in large population cohorts (gnomAD); Also known as R380W using alternative nomenclature; This variant is associated with the following publications: (PMID: 3362311, 20886637, 23319190, 27638593, 27126738, 21876145, 24297913, 31707742, 32186243, 31240153, 9338580, 26795590, 27638592, 21824559, 33178108, 31589614) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 18, 2019 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at